Advanced search
1 file | 810.64 KB Add to list

Pulmonary vein isolation with vs. without continued antiarrhythmic drug treatment in subjects with recurrent atrial fibrillation (POWDER AF) : results from a multicentre randomized trial

(2018) EUROPEAN HEART JOURNAL. 39(16). p.1429-1437
Author
Organization
Abstract
Aims: Catheter ablation is indicated in patients with symptomatic paroxysmal atrial fibrillation (AF) resistant to antiar- rhythmic drug therapy (ADT). We investigated whether continued use of previously ineffective ADT beyond the post-ablation blanking period reduces recurrence of atrial tachyarrhythmia within the 1st year after ablation. Methods and results: This was a multicentre, randomized controlled study in patients undergoing contact force-guided pulmonary vein isolation (PVI) for paroxysmal AF in whom previously ineffective ADT was continued during a blanking period of 3 months. If free of AF at the end of the blanking period, patients were randomly assigned in the ratio of 1:1 to continue ADT (ADT ON group, n= 77) or discontinue ADT (ADT OFF group, n= 76). Patients were followed up until 1 year after PVI, with clinical visits, Hotter monitoring, and quality-of-life (QOL) questionnaires at 6 and 12 months post-procedure. Analysis of the primary endpoint (any documented atrial tachyarrhythmia lasting >30 s) was performed according to the modified intention-to-treat principle. Secondary endpoints included repeat ablation, unscheduled visits, and QOL score. Baseline clinical characteristics and initial ablation procedure characteristics were comparable between both groups. Three patients were lost to follow-up in each arm. The primary endpoint was observed in 2 of 74 (2.7%) patients in the ADT ON group vs. 16 of 73 (21.9%) patients in the ADT OFF group (P<0.001). The ADT ON group had a tower rate of repeat ablation [1.4% vs. 19.2%, hazard ratio (HR) = 0.053; 95% confidence interval (CI) 0.007-0.399; P <0.01) and less unscheduled arrhythmia-related health care visits (2.7% vs. 20.5%, HR = 0.055, 95% CI 0.007-0.410; P<0.01). Quality-of-life scores were similar in both groups. Conclusion: In patients free of AF at the end of 3 months of post-ablation blanking period, continued use of previously ineffec- tive ADT significantly reduces the recurrence of atrial tachyarrhythmia in the 1st year after PVI.
Keywords
Atrial fibrillation, Ablation, Antiarrhythmic drugs, RADIOFREQUENCY CATHETER ABLATION, CRYOBALLOON, THERAPY

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 810.64 KB

Citation

Please use this url to cite or link to this publication:

MLA
Duytschaever, Mattias, et al. “Pulmonary Vein Isolation with vs. without Continued Antiarrhythmic Drug Treatment in Subjects with Recurrent Atrial  Fibrillation (POWDER AF) : Results from a Multicentre Randomized Trial.” EUROPEAN HEART JOURNAL, vol. 39, no. 16, 2018, pp. 1429–37.
APA
Duytschaever, M., Demolder, A., Phlips, T., Sarkozy, A., El Haddad, M., Taghji, P., … De Potter, T. (2018). Pulmonary vein isolation with vs. without continued antiarrhythmic drug treatment in subjects with recurrent atrial  fibrillation (POWDER AF) : results from a multicentre randomized trial. EUROPEAN HEART JOURNAL, 39(16), 1429–1437.
Chicago author-date
Duytschaever, Mattias, Anthony Demolder, Thomas Phlips, Andrea Sarkozy, Milad El Haddad, Philippe Taghji, Sebastien Knecht, Rene Tavernier, Yves Vandekerckhove, and Tom De Potter. 2018. “Pulmonary Vein Isolation with vs. without Continued Antiarrhythmic Drug Treatment in Subjects with Recurrent Atrial  Fibrillation (POWDER AF) : Results from a Multicentre Randomized Trial.” EUROPEAN HEART JOURNAL 39 (16): 1429–37.
Chicago author-date (all authors)
Duytschaever, Mattias, Anthony Demolder, Thomas Phlips, Andrea Sarkozy, Milad El Haddad, Philippe Taghji, Sebastien Knecht, Rene Tavernier, Yves Vandekerckhove, and Tom De Potter. 2018. “Pulmonary Vein Isolation with vs. without Continued Antiarrhythmic Drug Treatment in Subjects with Recurrent Atrial  Fibrillation (POWDER AF) : Results from a Multicentre Randomized Trial.” EUROPEAN HEART JOURNAL 39 (16): 1429–1437.
Vancouver
1.
Duytschaever M, Demolder A, Phlips T, Sarkozy A, El Haddad M, Taghji P, et al. Pulmonary vein isolation with vs. without continued antiarrhythmic drug treatment in subjects with recurrent atrial  fibrillation (POWDER AF) : results from a multicentre randomized trial. EUROPEAN HEART JOURNAL. 2018;39(16):1429–37.
IEEE
[1]
M. Duytschaever et al., “Pulmonary vein isolation with vs. without continued antiarrhythmic drug treatment in subjects with recurrent atrial  fibrillation (POWDER AF) : results from a multicentre randomized trial,” EUROPEAN HEART JOURNAL, vol. 39, no. 16, pp. 1429–1437, 2018.
@article{8545020,
  abstract     = {Aims: Catheter ablation is indicated in patients with symptomatic paroxysmal atrial fibrillation (AF) resistant to antiar- rhythmic drug therapy (ADT). We investigated whether continued use of previously ineffective ADT beyond the post-ablation blanking period reduces recurrence of atrial tachyarrhythmia within the 1st year after ablation. 
Methods and results: This was a multicentre, randomized controlled study in patients undergoing contact force-guided pulmonary vein isolation (PVI) for paroxysmal AF in whom previously ineffective ADT was continued during a blanking period of 3 months. If free of AF at the end of the blanking period, patients were randomly assigned in the ratio of 1:1 to continue ADT (ADT ON group, n= 77) or discontinue ADT (ADT OFF group, n= 76). Patients were followed up until 1 year after PVI, with clinical visits, Hotter monitoring, and quality-of-life (QOL) questionnaires at 6 and 12 months post-procedure. Analysis of the primary endpoint (any documented atrial tachyarrhythmia lasting >30 s) was performed according to the modified intention-to-treat principle. Secondary endpoints included repeat ablation, unscheduled visits, and QOL score. Baseline clinical characteristics and initial ablation procedure characteristics were comparable between both groups. Three patients were lost to follow-up in each arm. The primary endpoint was observed in 2 of 74 (2.7%) patients in the ADT ON group vs. 16 of 73 (21.9%) patients in the ADT OFF group (P<0.001). The ADT ON group had a tower rate of repeat ablation [1.4% vs. 19.2%, hazard ratio (HR) = 0.053; 95% confidence interval (CI) 0.007-0.399; P <0.01) and less unscheduled arrhythmia-related health care visits (2.7% vs. 20.5%, HR = 0.055, 95% CI 0.007-0.410; P<0.01). Quality-of-life scores were similar in both groups. 
Conclusion: In patients free of AF at the end of 3 months of post-ablation blanking period, continued use of previously ineffec- tive ADT significantly reduces the recurrence of atrial tachyarrhythmia in the 1st year after PVI.},
  author       = {Duytschaever, Mattias and Demolder, Anthony and Phlips, Thomas and Sarkozy, Andrea and El Haddad, Milad and Taghji, Philippe and Knecht, Sebastien and Tavernier, Rene and Vandekerckhove, Yves and De Potter, Tom},
  issn         = {0195-668X},
  journal      = {EUROPEAN HEART JOURNAL},
  keywords     = {Atrial fibrillation,Ablation,Antiarrhythmic drugs,RADIOFREQUENCY CATHETER ABLATION,CRYOBALLOON,THERAPY},
  language     = {eng},
  number       = {16},
  pages        = {1429--1437},
  title        = {Pulmonary vein isolation with vs. without continued antiarrhythmic drug treatment in subjects with recurrent atrial  fibrillation (POWDER AF) : results from a multicentre randomized trial},
  url          = {http://dx.doi.org/10.1093/eurheartj/ehx666},
  volume       = {39},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: